Nfatc1 Is a Functional Transcriptional Factor Mediating Nell-1-Induced Runx3 Upregulation in Chondrocytes. by Li, Chenshuang et al.
UCLA
UCLA Previously Published Works
Title
Nfatc1 Is a Functional Transcriptional Factor Mediating Nell-1-Induced Runx3 
Upregulation in Chondrocytes.
Permalink
https://escholarship.org/uc/item/4cq7z5rj
Journal
International journal of molecular sciences, 19(1)
ISSN
1422-0067
Authors
Li, Chenshuang
Zheng, Zhong
Zhang, Xinli
et al.
Publication Date
2018-01-06
DOI
10.3390/ijms19010168
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 International Journal of 
Molecular Sciences
Communication
Nfatc1 Is a Functional Transcriptional Factor
Mediating Nell-1-Induced Runx3 Upregulation
in Chondrocytes
Chenshuang Li 1,†, Zhong Zheng 1,† ID , Xinli Zhang 1, Greg Asatrian 1, Eric Chen 1,
Richard Song 1, Cymbeline Culiat 2, Kang Ting 1,* and Chia Soo 3,*
1 Division of Growth and Development, Section of Orthodontics, School of Dentistry, University of California,
Los Angeles, Los Angeles, CA 90095, USA; chenshuanglee@gmail.com (C.L.);
zzheng@dentistry.ucla.edu (Z.Z.); xinli@ucla.edu (X.Z.); gasatrian@ucla.edu (G.A.);
ericchenucla@g.ucla.edu (E.C.); richardsong227@gmail.com (R.S.)
2 NellOne Therapeutics, Inc., 99 Midway Ln # E, Oak Ridge, TN 37830, USA; cymbeline@nell-one.com
3 Division of Plastic and Reconstructive Surgery and Department of Orthopaedic Surgery, the Orthopaedic
Hospital Research Center, University of California, Los Angeles, Los Angeles, CA 90095, USA
* Correspondence: kting@dentistry.ucla.edu (K.T.); bsoo@ucla.edu (C.S.);
Tel.: +1-310-206-6305 (K.T.); +1-310-794-5479 (C.S.)
† These authors contributed equally to this work.
Received: 4 December 2017; Accepted: 5 January 2018; Published: 6 January 2018
Abstract: Neural EGFL like 1 (Nell-1) is essential for chondrogenic differentiation, maturation,
and regeneration. Our previous studies have demonstrated that Nell-1’s pro-chondrogenic activities
are predominantly reliant upon runt-related transcription factor 3 (Runx3)-mediated Indian hedgehog
(Ihh) signaling. Here, we identify the nuclear factor of activated T-cells 1 (Nfatc1) as the key
transcriptional factor mediating the Nell-1 → Runx3 signal transduction in chondrocytes. Using
chromatin immunoprecipitation assay, we were able to determine that Nfatc1 binds to the−833–−810
region of the Runx3-promoter in response to Nell-1 treatment. By revealing the Nell-1→ Nfatc1→
Runx3→ Ihh cascade, we demonstrate the involvement of Nfatc1, a nuclear factor of activated T-cells,
in chondrogenesis, while providing innovative insights into developing a novel therapeutic strategy
for cartilage regeneration and other chondrogenesis-related conditions.
Keywords: neural EGFL like 1 (Nell-1); nuclear factor of activated T-cells 1 (Nfatc1); runt-related
transcription factor 3 (Runx3); chondrogenesis
1. Introduction
A diverse group of molecules is involved in the regulation of chondrogenic differentiation, an
essential process for bone and cartilage formation [1]. Previous studies demonstrated that neural
EGFL like 1 (Nell-1) enhanced chondrogenic marker expression and cartilage nodule formation
in rabbit chondrocytes [2]. Additionally, Nell-1 administration has been observed to induced
hyaline cartilage regeneration in a rabbit knee subchondral defect model [3], and implantation of
Nell-1-overexpressing bone marrow mesenchymal stem cells into critical-sized goat mandibular
condyle osteochondral defects resulted in articular cartilage reestablishment [4]. Conversely,
homozygous N-ethyl-N-nitrosourea (ENU)-induced Nell-1-deficient mice fail to survive perinatally,
accompanied by shorter and deformed rib cages and vertebral bodies, compressed intervertebral
spaces, and reduced expression of cartilage matrix in comparison with those of the wild-type and
heterozygous littermates [5]. Our recent studies demonstrated that, in chondrocytes, the expression
of Nell-1 is regulated by the runt-related transcription factor 2 (Runx2) [6], a pivotal transcriptional
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factor regulating chondrogenesis [7]. Interestingly, Nell-1’s pro-chondrogenic activities extended to
Runx2−/− scenarios by stimulating the expression and signal transduction of runt-related transcription
factor 3 (Runx3) and its downstream target Indian hedgehog (Ihh) [6,8].
Previous findings suggested that Runx3 is not one of the early response genes during
Nell-1-regulated chondrogenesis [9]. As such, it is critical to identify the molecule(s) mediating
the Nell-1-stimulated Runx3 expression to further elucidate the mechanism of action of Nell-1 in
chondrogenesis. In this study, we first screened key transcriptional factors bridging the Nell-1 →
Runx3 signal transduction using a two-step in silico promoter analysis and quantitative real-time PCR
(qPCR) strategy. These findings were further validated using RNA interference (RNAi) technology.
Subsequently, we used chromatin immunoprecipitation (ChIP) assay to recognize the binding site
of the identified key Nell-1-induced transcriptional factor on the Runx3 promoter. The current
study is not only an additional new section of a series of investigations that uncover the underlying
mechanism of Nell-1’s function in chondrogenesis, but also demonstrates the involvement of Nfatc1,
a nuclear factor of activated T-cells, in chondrogenesis, while providing innovative insights that
will assist in the development of a novel therapeutic strategy for cartilage regeneration and other
chondrogenesis-related conditions.
2. Results
2.1. Runt-Related Transcription Factor 1 (Runx1) and Nfatc1 Were Selected as the Candidates That Bridge
Nell-1→ Runx3 Signal Transduction in Chondrocytes
Using in silico bioinformatics software Genomatix to predict the binding candidates of mouse
Runx3 promoter, we identified 22 cartilage/chondrocyte-expressed transcriptional factor candidates
(Table 1). Compared with previous microarray data that screened the primary response genes of
Nell-1-mediated chondrogenesis (GEO DataSet: GSE23570) [9] as a reference, it was observed that
runt-related transcription factor 1 (Runx1), T-cell leukemia, homeobox1 (Tlx1), nuclear factor of activated
T-cells 1 (Nfatc1; previously known as nuclear factor of activated T-cells, cytoplasmic calcineurin-dependent 1
and also known as Nfat2 and Nfatc), and nuclear factor of activated T-cells 5 (Nfat5) were significantly
upregulated by Nell-1 in chondrogenic-committed ATDC5 cells and were therefore selected for further
investigation in the current study.
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Table 1. Mouse Runx3 promoter binding transcriptional factor candidates that expressed in cartilage and chondrocytes.
In Silico Bioinformatics Predicted Mouse Runx3 Promoter Binding Transcriptional Factors That Expressed in Cartilage and Chondrocytes Gene Expression Changes in ATDC5Cells Due to the Nell-1 Treatment *
Matrix Family Gene Full Name Strand Sequence ** Matrix Similarity Fold-Change p-Value
FKHD
Foxp1 Forkhead box P1 (−) 5′-gggtcaaAACAgagggg-3′ 1 1.14 5.7 × 10−6
Foxp2 Forkhead box P2 (+) 5′-cagcagtaAACAgagag-3′ 0.994 0.79 1.1 × 10−2
Hnf3b/Foxa2 Hepatic nuclear factor 3 beta (+) 5′-cagcagtaAACAgagag-3′ 0.914 0.32 2.0 × 10−2
Foxo1 Forkhead box protein O1 (+) 5′-aaaaagtcAACAcctcc-3′ 0.9 0.73 7.9 × 10−5
Fhx/Foxj2 Fork head homologous X binds DNA with a dualsequence specificity (FHXA and FHXB) (+) 5
′-gtagccACAAgatcttc-3′ 0.835 0.84 2.6 × 10−5
HAML Runx1 Runt-related transcription factor 1 (+) 5′-ctgtGTGGtccggac-3′ 0.97 1.23 8.8 × 10−5
HOMF
Hhex
Hematopoietically expressed homeobox,
proline-rich homeodomain protein
(+) 5′-aactaggtgttTAATtttg-3′ 0.969
0.90 3.0 × 10−4(+) 5′-ttcccaccattTAATgata-3′ 0.952
Hmx3
H6 homeodomain HMX3/Nkx5.1
transcription factor
(+) 5′-cggaccccAAGTgcctcca-3′ 0.897
2.99 0.19 ***(+) 5′-ggctcaggAAGTgggggtg-3′ 0.911
(+) 5′-agccaaccAAGTgggtctg-3′ 0.96
Msx-1 Homeodomain proteins MSX-1 and MSX-2 (+) 5′-aggtgttTAATtttgcaac-3′ 0.989 0.81 4.5 × 10−4
Hmx2 Hmx2/Nkx5-2 homeodomain transcription factor (−) 5′-gtatcaTTAAatggtggga-3′ 0.86 0.90 0.69 ***
Tlx1/Hox11 T-cell leukemia, homeobox 1 (−) 5′-tgggagcCGCTgagtgggt-3′ 0.858 1.41 3.0 × 10−2
NFAT
Nfatc1 Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 1, dimeric binding site
(−) 5′-tttaccGTGGaacccagga-3′ 0.826
1.55 5.3 × 10−4(+) 5
′-ggttccACGGtaaagccag-3′ 0.816
(−) 5′-atctccAAGGaaagaaagt-3′ 0.827
(+) 5′-ctttccTTGGagattttct-3′ 0.877
Nfat5 nuclear factor of activated T-cells 5 (−) 5′-ccaaGGAAagaaagtttcg-3′ 0.844 1.52 6.0 × 10−5
SORY
Sox1 SRY (sex determining region Y)-box 1, dimericbinding sites (−) 5
′-gctGATTccccactcaggcagag-3′ 0.795 0.43 0.14 ***
Sox21
SRY (sex determining region Y)-box 21, dimeric
binding sites
(−) 5′-cctGCATgttggtcacacaacta-3′ 0.783
ND **** ND ****(+) 5′-attTAATgatactctgcacatag-3′ 0.762
Sox2 SRY-box containing gene 2, dimeric binding sites (−) 5′-gatCAAGggtgtgaatagagtcc 0.701 0.90 8.7 × 10−6
Sox8
SRY (sex determining region Y)-box 8, dimeric
binding sites
(−) 5′-aatGAAAggcagtactgacctgc-3′ 0.777
ND **** ND ****(+) 5′-cagGACTcccagtctcacagggt-3′ 0.763
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Table 1. Cont.
In Silico Bioinformatics Predicted Mouse Runx3 Promoter Binding Transcriptional Factors That Expressed in Cartilage and Chondrocytes Gene Expression Changes in ATDC5Cells Due to the Nell-1 Treatment *
SORY
Hbp1 high mobility group box transcription factor 1
(−) 5′-aatgaatgAATGaacgaggctca-3′ 1
0.84 3.8 × 10−5(−) 5
′-gatgaatgAATGaatgaacgagg-3′ 1
(−) 5′-ctggatgAATGaatgaatgaacg-3′ 0.996
(−) 5′-cagcctgGATGaatgaatgaatg-3′ 0.847
Sox9 SRY (sex determining region Y)-box 9 homodimer
(+) 5′-acAGAAagcctaccttctctctc-3′ 0.787
0.76 1.1 × 10−5(+) 5′-gaaccACAAggccaggccctcgc-3′ 0.944
(−) 5′-gcaCTATgtgcagagtatcatta-3′ 0.733
HMGI(Y) high-mobility-group protein I (Y),
Hmgiy/Hmga1
architectural transcription factor organizing the
framework of a nuclear protein-DNA transcriptional
complex /High mobility group AT-Hook 1
(−) 5′-cacaAATTttcaacagcactatg-3′ 0.935
0.56 1.5 × 10−3(+) 5′-tgaaAATTtgtggctagacattc-3′ 0.935
Sox10 SRY-box containing gene 10 (−) 5′-caGGAAtgtctagccacaaattt-3′ 0.739 8.25 0.54 ***
PAX Pax1 Pax1 paired domain protein, expressed in thedeveloping vertebral column of mouse embryos (−) 5
′-cTGTTttgttatatatatt-3′ 0.667 ND **** ND ****
* Data are subtracted from the GEO DataSet: GSE23570; ** Capitalized characters represent the core sequence; *** Not statically significant; **** Not detected in the published dataset (GEO
DataSet: GSE23570) using Affymetrix Mouse Genome Array.
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Although preliminary microarray assay revealed that Nell-1 upregulated the expression of
all four potential candidate genes [9], qPCR demonstrated that Nell-1 only significantly elevated
Runx1 and Nfatc1 expression in ATDC5 cells (Figure 1a). To eliminate the influence of Runx2, which
could significantly induce Nell-1 expression in chondrocytes [6] and stimulate their proliferation,
differentiation, and hypertrophy [10–12], these four Nell-1-responsive transcriptional factor candidates
were further validated in Runx2−/− chondrocytes [6,8]. Like in ATDC5 cells, Nell-1 did not alter Tlx1
expression in Runx2−/− chondrocytes (Figure 1b). Interestingly, in Runx2−/− chondrocytes, while only
high dose Nell-1 slightly increased Runx1 and Nfat5, all tested doses of Nell-1 upregulated Nfatc1
expression significantly (Figure 1b). Moreover, the expression of Tlx1 and Nfat5 remained consistent in
chondrocytes with different Nell-1 genotypes, while expression of Runx1 and Nfatc1 was significantly
reduced in Nell-16R/6R chondrocytes (Figure 1c). Of the four tested transcriptional factor candidates,
only Nfatc1 was downregulated in Nell+/6R chondrocytes (Figure 1c), suggesting that Nfatc1 is more
sensitive to Nell-1 levels when compared to Runx1. Immunofluorescent (IF) staining confirmed a
similar protein expression pattern of these candidates in the neonatal mouse femurs (Figure 2). Thus,
Runx1 and Nfatc1 were selected for further investigation.
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Figure 1. Nell-1 selectively alters the expression levels of Runx3-promoter binding candidates in
chondrocytes. (a) Expression levels of Runx3-pro oter binding candidates in monolayer cultured
ATDC5 cells after stimulation ith exogenous ell-1 for 3 h. *: p < 0.05 vs. 0 µg/mL Nell-1;
(b) Expression levels of Runx3-promoter binding candidates in monolayer cultured Runx2−/− rib
chondrocytes after stimulation i us Nell-1 for 12 h. *: p <0.05 vs. 0 µg/mL Nell-1;
(c) Expression l vels of Runx3-promoter binding candidates i ib chondrocyt s with different
genotypes of Nell-1. *: p < 0.05 vs. Nell-1+/+ chondrocytes; #: p < 0.05 vs. Nell-1+/6R chondrocytes. Mean
+ SD of three (a,b) or six (c) independent experiments performed in triplicate are shown.
2.2. Knockdown Runx1 Failed to Demonstrate the Effects on the Nell-1-Mediated Runx3-Ihh Signaling
In the 2D monolayer-cultured Runx2−/− chondrocytes, Runx1 knockdown by shRNA did not
change the basal expression levels of Runx3, Acan (encoding aggrecan, a Runx3 downstream major
structural component in cartilage matrix [7,13]), Ihh, Ptch1 (encoding Ihh downstream target patched
homology 1 (Patched 1)), and Gli1 (encoding Ihh-responsive Gli1) (Figure 3a). Interestingly, Nell-1
significantly increased the expression of these genes in Runx1-knockdown Runx2−/− chondrocytes
to levels comparable to that of the control shRNA + 2.0 µg/mL Nell-1 group (Figure 3a). Similar
findings were observed in the 3D cultured Runx2−/− chondrocyte micromass: the transcription of
Runx3–related (Runx3 and Acan), Ihh signaling-related (Ihh and Ptch1), chondrogenic differentiation
related genes Col2α1 (encoding the α1 chain of type II collagen, an abundant and specific protein in
cartilage [1,7]) and Sox9 (encoding the master transcription factor for chondrogenesis initiation SRY-Box
9 [1,7]) (Figure 3b); also, Alcian Blue staining intensity (Figure 3c,d) was almost at the same levels as
in the control shRNA + 0 µg/mL Nell-1 and Runx1 shRNA + 0 µg/mL Nell-1 groups. Furthermore,
there were no significant differences observed between the control shRNA + 2.0 µg/mL Nell-1 and
Runx1 shRNA + 2.0 µg/mL Nell-1 groups with regard to these indexes (Figure 3b–d). Thus, it can be
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concluded that Runx1 does not actively participate in the Nell-1 activation of Runx3-Ihh signaling in
chondrocytes, at least when Runx2 is absent.
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Figure 2. Immunofluorescent (IF) staining of Runx3-promoter binding transcriptional factor candidates
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detected on the red blood cells. Scale bar = 50 µm.
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bioactivities on Runx3-Ihh signal activation and chondrogenic stimulation were abrogated by the 
Nfatc1 knockdown. 
Figure 3. Runx1 knockdown does not alter the Nell-1’s effects on Runx3-Ihh signaling activation and
chondrogenesis of Runx2−/− rib chondrocytes. (a) Transcription of Runx3 and Ihh signal-related
molecules in monolayer cultured Runx2−/− rib chondrocytes after 12-h stimulation of Nell-1;
(b) Transcription of Runx3 and Ihh signal-related molecules in 3D micromass cultured Runx2−/−
chondrocytes after 3-day stimulation of Nell-1; (c) Alcian Blue staining of 3D micromass cultured
Runx2−/− chondrocytes after 3-day stimulation of Nell-1; (d) Alcian Blue incorporation into
the extracellular matrix of micromass cultures reflecting the production of the proteoglycan-rich
cartilaginous matrix at day 3 was quantified after extraction. The dye concentration of each group was
normalized to that of the control shRNA + 0 µg/mL Nell-1 group. Mean + SD of three independent
experiments performed in triplicate are shown. *: p < 0.05 vs. control shRNA + 0 µg/mL Nell-1, #:
p < 0.05 vs. control shRNA + 2.0 µg/mL Nell-1, &: p < 0.05 vs. Runx1 shRNA + 0 µg/mL Nell-1.
2.3. Nfatc1 Mediates Nell-1’s Role in Runx3-Ihh Signaling and Chondrogenic Differentiation
Although Nfatc1 knockdown by shRNA did not significantly alter the basal expression levels
of either Runx3 and its downstream target Acan, or of Ihh signaling-related genes (Ihh and Ptch1)
in Runx2−/− chondrocytes, Nell-1’s stimulation of these genes was completely nullified by Nfatc1
knockdown (Figure 4a). Moreover, in the 3D cultured Runx2−/− chondrocyte micromass that
underwent chondrogenic differentiation, Nell-1 was neither able to upregulate the expression of
all tested genes or to enhance Alcian Blue staining in the Nfatc1-knockdown Runx2−/− chondrocyte
micromass (Figure 4b–d). Importantly, when Nfatc1 was knocked down by shRNA transfection in
Runx2−/− chondrocytes, the expression of Sox9 in the 3D cultured Runx2−/− chondrocyte micromass
was significantly downregulated with or without the treatment of Nell-1, which indicates that
the initiation of Nell-1-mediated chondrogenesis was blocked (Figure 4b). In aggregate, Nell-1’s
bioactivities on Runx3-Ihh signal activation and chondrogenic stimulation were abrogated by the
Nfatc1 knockdown.
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specific antibody demonstrated enrichment of the −833–−810 fragment of the Runx3 promoter in 
Runx2−/− chondrocytes, which was further enhanced by Nell-1 stimulation. Meanwhile, ChIP analysis 
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Figure 4. Nfatc1 is the bridging molecule between Nell-1 and the Runx3-Ihh signaling pathway in
Runx2−/− rib chondrocytes. (a) Transcription of Runx3 and Ihh signal-related molecules in monolayer
cultured Runx2−/− rib chondrocytes after 12-h stimulation of Nell-1; (b) Transcription of Runx3 and
Ihh signal-related molecules in 3D micromass cultured Runx2−/− chondrocytes after 3-day stimulation
of Nell-1; (c) Alcian Blue staining of 3D micromass cultured Runx2−/− chondrocytes after 3-day
stimulation of Nell-1; (d) Alcian Blue incorporation into the extracellular matrix of micromass cultures
reflecting the production of the proteoglycan-rich cartilaginous matrix at day 3 was quantified after
extraction. The dye concentration of each group was normalized to that of the control shRNA + 0
µg/mL Nell-1 group. Mean + SD of three independent experiments performed in triplicate are shown.
*: p < 0.05 vs. control shRNA + 0 µg/mL Nell-1, #: p < 0.05 vs. control shRNA + 2.0 µg/mL Nell-1.
2.4. Nell-1 Enhances the Binding of Nfatc1 at the −833–−810 Region of Runx3 Promoter in Chondrocytes
Based on the in silico findings, two potential binding sites of Nfatc1 were predicted on the promoter
of Runx3: −280–−257 (ACT TTC TTT CCT TGG AGA TTT TCT) and −833–−810 (ACC TGG GTT
CCA CGG TAA AGC CAG). Using both non-specific IgG and Nfatc1-specific antibody, ChIP assays
were carried out. Negligible levels of DNA accumulation were observed at the −280–−257 region,
regardless of treatment with Nell-1 (Figure 5). Conversely, ChIP analysis using the Nfatc1-specific
antibody demonstrated enrichment of the −833–−810 fragment of the Runx3 promoter in Runx2−/−
chondrocytes, which was further enhanced by Nell-1 stimulation. Meanwhile, ChIP analysis using
a negative control IgG demonstrated minimal enrichment of this DNA sequence with or without
exogenous Nell-1 treatment (Figure 5). Therefore, our ChIP assays indicated that Nfatc1 binds to the
−833–−810 region of the Runx3-promoter in chondrocytes, and this binding is significantly enhanced
by Nell-1.
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3. Discussion
Nearly two decades ago, Nell-1 was first observed to be upregulated in prematurely fusing
and fused sutural sites of craniosynostosis (CS) patients [14], suggesting Nell-1’s involvement
in osteochondral development. Subsequently, our team has demonstrated that transgenic Nell-1-
overexpression (CMV-Nell-1) mice recapitulate human CS-like phenotypes [15,16]. On the other hand,
homozygous Nell-1-deficient mice were noted to exhibit neonatal lethality with reduced calvarial bone
thickness and density similar to those of calvarial cleidocraniodysplastic patients [5,17,18]. These
phenomena strongly indicate that Nell-1 is pivotally involved in osteogenic development.
Nell-1 also exerts pro-chondrogenic bioactivities on both mesenchymal stem cells (MSCs) and
chondrogenic-committed cells [6]. Until present, however, the function of Nell-1 in chondrogenesis
has not attracted enough attention, and thus the mechanism of action of Nell-1 in chondrogenic
differentiation remained largely elusive. Our recent studies have shown that Runx2 upregulates
Nell-1 expression in chondrocytes, while Runx2-deficiency leads to significantly reduced Nell-1 levels,
signifying that regulation of Runx2 has a profound impact on Nell-1 during chondrogenesis [6].
Unlike the mutual regulation between Nell-1 and Runx2 observed in osteoblast lineage cells [19–21],
Nell-1 does not upregulate Runx2 in chondrocytes [6]. Further studies have also revealed that, as a
downstream mediator of Runx2, Nell-1’s pro-chondrogenic effect relies on the activation of Ihh
signaling [8]. Unlike Runx2, however, which can directly bind to Ihh-promoter [10,22], Nell-1-mediated
upregulation of Ihh signaling was under the control of Runx3 [8], and therefore Nell-1 is able to
partially rescue Runx2-deficiency-induced impaired chondrogenic differentiation and maturation [6,8].
In the current study, we have successfully identified and functionally validated Nfatc1 as the key
transcriptional factor that bridges Nell-1 stimulation and Runx3 upregulation in chondrocytes. Nfatc1
functions as a key early Nell-1-response target in chondrocytes, upregulating Runx3 expression via
binding to its promoter at −833–−810 region and thus activating the Runx3-Ihh signal transduction
cascade in order to induce chondrogenic differentiation and maturation (Figure 6). However, recent
studies indicate that, as an 810-amino-acid secreted protein with multiple N-linked glycan chains,
Nell-1 may function as oligomers [17]. Although the binding of Nell-1 with integrin β1 has been
detected previously [23,24], Nell-1’s cell surface functional receptor(s) that initiates intracellular signal
transduction, particularly in chondrogenic-committed cells, has yet to be discovered. Future studies
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through a global collaboration are warranted in order to gain a comprehensive understanding of
the molecular mechanisms, especially the details of how Nell-1 stimulates Nfatc1 expression and
modulates its activity. Nevertheless, the previously unrecognized Nell-1→ Nfatc1→ Runx3→ Ihh
cascade provides innovative insights into developing a novel, therapeutic platform for managing
cartilage regeneration and other chondrogenesis-related conditions.
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Figure 6. Schematic diagram of Nell-1 signaling pathways during chondrogenesis. (a) Nell-1 promotes
Nfatc1 expression; (b) Nfatc1 next binds to the promoter of Runx3, activating the Runx3 signal
transduction (c) as well as the Ihh signal transduction (d) to stimulate the differentiation and maturation
of chondrocytes (e). Black arrows, previously revealed knowledge; green solid arrow, current uncovered
regulation mechanism; green dashed arrow, a current suggested regulation mechanism which needs
further investigation; T bar, known inhibitory effect.
Although Nfatc1–4 are all expressed in murine chondrocytes, only the regulatory effects of Nfatc1
and Nfatc2 on chondrogenesis were evaluated [25–27]. Since in silico predictions did not find the
potential binding site of Nfatc2 on Runx3 promoter, Nfatc2 was not further investigated in this study.
In 2010, Sohn et al. detected the expression of Nfatc1 in the intervertebral disc of E12.5-day old mice
embryos and concluded this expression was upregulated by transforming growth factor β1, but not
bone morphogenetic protein 4, in sclerotome micromass culture [28]. In 2013, Zanotti and Canalis
pioneered the investigation of Nfatc1’s function during chondrogenesis by demonstrating that forcing
overexpression of Nfatc1 in mouse primary chondrocytes reduced the expression of Sox9 and Col2α1
at day 3 and Col10α1 (encoding the α1 chain of type X collagen) expression at day 21 [29]. Moreover,
Ge et al. revealed that Nfatc1 restricts the proliferation and chondrogenesis of osteochondroma
precursors [30]. Although there is no significant difference reported between Nfatc1-mutant and
wild-type mice during normal cartilage development or in the post-traumatic osteoarthritis animal
model, cartilage-specific ablation of Nfatc1 in Nfatc2−/− mice markedly accelerated osteoarthritis
development [31], which indicates that Nfatc1 may act as an osteoarthritis-suppressor. This study
is the first report that clearly demonstrates the essential pro-chondrogenic role of Nfatc1 in mouse
primary chondrocytes and reveals the potential underlying mechanism. In supporting the current
understanding that “NFATs are good for your cartilage!” [32], our current discovery highlights the
essential modulatory nature of Nfatc1 beyond its function as a regulator of inflammation [33] and
enriches our knowledge about the myriad of complex interactions among a diverse group of growth
factors and transcriptional factors during chondrogenesis.
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4. Materials and Methods
4.1. In Silico Promoter Analysis
Genomatix software suite v3.4 (Genomatix AG, Munich, Germany) was used to predict
transcriptional factor binding motifs on the Runx3 promoter. Sites were computationally projected with
predefined transcription factor binding modules [34] in the Promoter Module Library (Genomatix).
4.2. Animal Maintenance
Mice were bred and maintained as previously described [5,15,20,35] under institutionally
approved protocol provided by the Chancellor’s Animal Research Committee at UCLA (protocol
number: 2012-041; 15 September 2012). Runx2 haploinsufficient mice (Runx2+/− [35]) were mated with
Nell-1-overexpressing mice (CMV-Nell-1 [15]) to obtain Runx2−/−/CMV-Nell-1 mice [20]. Due to the
severe reduction of Nell-1 expression in homozygotes (Nell-16R/6R; Nell-16R: an ENU-induced point
mutation truncating an 810 amino-acid Nell-1 protein at residue no. 502 [36,37]), neonatal death was
induced [5]. Heterozygous Nell-16R mice (Nell-1+/6R) were used to produce Nell-16R/6R fetuses. Mouse
genotypes were determined by PCR [5,15,20,35].
4.3. Immunofluorescence (IF) Staining
Animals used in this study were euthanized via phenobarbital (Piramal Healthcare, Maharashtra,
India) overdose. Hind limbs, isolated from neonatal mice, were fixed in 4% paraformaldehyde at 4 ◦C
overnight before paraffin embedding and sectioning at 5-µm. IF staining was performed following the
instruction of ”abcam protocol book” (Abcam, available at http://docs.abcam.com/pdf/misc/abcam-
protocols-book-2010.pdf). All primary antibodies were purchased from Abcam (Cambridge, MA,
USA), IHC-TekTM Antibody Diluent pH7.4 (IHCWORD, Woodstock, MD, USA) and were used for
blocking and antibody dilution; Dnk pAb to Rb IgG (Alexa Fluor® 488) (ab150073, Abcam) was used
as the second antibody and 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI; Sigma-Aldrich,
St. Louis, MO, USA) was used for nuclear counterstaining.
4.4. Cultivation of ATDC5 Cell Line
A well-known chondrogenic-committed cell line, ATDC5 [38], was firstly used for the candidate
transcriptional factor screening. ATDC5 cells were obtained from the RIKEN Cell Bank (Tsukuba,
Japan) and cultured in ATDC maintenance medium composed of a 1:1 mixture of Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F-12 medium containing 5% fetal bovine serum (FBS), 10 mg/mL
of human transferrin (Sigma-Aldrich, St. Louis, MO, USA), and 30 nM sodium selenite (Sigma-Aldrich)
at 37 ◦C in a humidified atmosphere consisting of 5% CO2 and 95% air. All cell culture media were
purchased from Invitrogen (Carlsbad, CA, USA). Subconfluent ATDC5 cells were subjected to serum
starvation (0.1% FBS) for 18 hours and stimulated with recombinant human Nell-1 protein for 3 h as
previously described [8].
4.5. Mouse Primary Chondrocyte Isolation and Cultivation
Mouse primary chondrocyte isolation was conducted following the protocol provided by Dr.
Karen Lyons’ lab at UCLA, which is available at: https://www.mcdb.ucla.edu/Research/Lyons/
Protocols_files/Isolation_of_Sternal_Chondrocytes.pdf. Briefly, after removing soft tissues with
2 mg/mL protease (Roche, Nutley, NJ, USA) in PBS and 3 mg/mL collagenase II (Roche) in DMEM,
rib cages of neonatal mouse embryos were incubated in 1 mg/mL collagenase II for 3 h to achieve
single-cell suspension. After rinsing with DMEM, chondrocytes were cultured in a basal culture
medium (DMEM with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin). The medium
was changed every 3 days and cells were passaged at 70–90% confluence [6,8].
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5 × 104 cells/well P2 chondrocytes were seeded in 6-well plates with basal culture medium for
6 h. Recombinant human Nell-1 protein was synthesized by Aragen Bioscience Inc. (Morgan Hill, CA,
USA) with a purity of 92%. Before treatment, cells were synchronized by being cultured in a starvation
medium (DMEM + 1% ITS Universal Cell Culture Supplement Premix (BD Biosciences, San Jose, CA,
USA)) for 18 h [6,8].
For 3D micromass culture, cells were reconstituted in the culture medium at a density of 1 ×
107 cells/mL, and 10 µL of cell suspension was dropped into each well of a 24-well plate. The cell
culture plates were incubated in a 37 ◦C incubator for 3 h before adding culture medium to allow cells
to attach to the dish [6,8].
4.6. RNAi
Plasmid packages harboring shRNA targeting mouse Nfatc1 and Runx1, respectively, were
obtained from Origene (Rockville, MD, USA). For each package, there were four shRNA plasmids
harboring different sequences against the target genes. P2 chondrocytes isolated from Runx2−/− mice
were transfected with the shRNA plasmid with Lipofectamine 3000 reagent (Invitrogen). A control
shRNA plasmid provided by OriGene was also used to transfect Runx2−/− mouse chondrocytes.
Transfection efficiency was determined by qPCR.
4.7. ChIP Assay
ChIP assay was performed by using the Pierce Magnetic ChIP Kit (Thermo Fisher Scientific Inc.,
Waltham, MA, USA) following the manufacturer’s instruction. 4 × 106 Runx2−/− chondrocytes were
used per ChIP reaction. After being synchronized in the starvation medium for 18 h, cells were treated
with Nell-1 for 12 h. 5 µg of a ChIP grade Nfatc1 primary antibody (Thermo Fisher Scientific Inc.) was
used for each target-specific IP. qPCR analysis was performed to qualify the DNA fragments pulled
down by antibodies. The primer sequences used are: −833–−810 locus: Forward: 5′-CTGGGG AAG
AGT CAG CAG GTC A-3′, Reverse: 5′-GTG GAT CTG GCT TTA CCG TGG A-3′; −280–−257 locus:
Forward: 5′-TGT GGG ACT GGG AAG CCA AAT-3′, Reverse: 5′-GGG AAA GAA CGC GAG AGC
GT-3′.
4.8. qPCR
Total RNA was isolated by TRIzol® Reagent (Invitrogen) followed by DNase (Invitrogen)
treatment. 1 µg RNA was injected for reverse transcription (RT) with the SuperScript II Reverse
Transcriptase Kit (Invitrogen). qPCR was performed on the 7300 Real-Time PCR system with SYBR
Green Mastermix (Invitrogen). All the primer sequences used are listed in Table 2. Concomitant
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was also evaluated in separate tubes for each RT
reaction as a housekeeping standard. Relative gene expression was analyzed by ∆∆CT method [39].
Table 2. Primer sequences used for real-time PCR.
Gene Primer Sequence
Acan
5′-CCA GGC TCC ACC AGA TAC TC-3′
5′-TGC TCA TAG CCT GCC TCA TA-3′
Col2α1
5′-GTC CTG AAG GTG CTC AAG GT-3′
5′-TTT GGC TCC AGG AAT ACC AT-3′
Gapdh 5
′-ATT CAA CGG CAC AGT CAA GG-3′
5′-GAT GTT AGT GGG GTC TCG CTC-3′
Gli1
5′-CCA AGC CAA CTT TAT GTC AGG G-3′
5′-AGC CCG CTT CTT TGT TAA TTT GA-3′
Int. J. Mol. Sci. 2018, 19, 168 13 of 16
Table 2. Cont.
Gene Primer Sequence
Ihh
5′-CTC AGA CCG TGA CCG AAA TAA G-3′
5′-CCT TGG ACT CGT AAT ACA CCC AG-3′
Nfat5 5
′-TGC TTT CTC AGC TTA CCA CGG-3′
5′-GTC CGC ACA ACA TAG GGC TC-3′
Nfatc1 5
′-GGA GAG TCC GAG AAT CGA GAT-3′
5′-TTG CAG CTA GGA AGT ACG TCT-3′
Ptch 1
5′-TGC CAC AGC CCC TAA CAA AAA-3′
5′-ACC CAC AAT CAA CTC CTC CTG-3′
Runx1
5′-ACG ATG AAA ACT ACT CGG CAG-3′
5′-CTG AGG TCG TTG AAT CTC GCT-3′
Runx3
5′-CAG GTT CAA CGA CCT TCG ATT-3′
5′-GTG GTA GGT AGC CAC TTG GG-3′
Sox9
5′-ACG GCT CCA GCA AGA ACA AG-3′
5′-TTG TGC AGA TGC GGG TAC TG-3′
Tlx1
5′-CGG CTT GCC TAC AGT ACC C-3′
5′-CTG CGG TTA CTC TCC ATC CAG-3′
4.9. Alcian Blue Staining and Quantification
Alcian Blue staining was performed by fixing micromass cultures at day 3 and then incubating
them with 0.1% Alcian Blue, pH 2.5, for 2 h. Quantification of the staining was achieved after extensive
washing with water by extraction with 6 M guanidine-hydrogen chloride for 8 h at room temperature.
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dye concentrations were
determined spectrophotometrically at A630 [40].
4.10. Statistical Analysis
All statistical analyses were conducted in consultation with the UCLA Statistical Biomathematical
Consulting Clinic. ANOVA and two-sample t-tests were computed by OriginPro 8 (Origin Lab Corp.,
Northampton, MA, USA) for statistical analysis. p-Value < 0.05 was considered statistically significant.
5. Conclusions
In this study, we identified and functionally validated Nfatc1 as a key transcriptional factor
mediating Nell-1→ Runx3 signal transduction in chondrocytes by binding to the -833 - -810 region
of Runx3-promoter. It is the first report that clearly demonstrates the essential pro-chondrogenic role
of Nfatc1 in mouse primary chondrocytes and reveals the potential underlying mechanism. As an
additional section of a series of investigations that uncover the underlying mechanism of Nell-1’s
function in chondrogenesis, this study provides innovative insights into developing a novel therapeutic
platform for managing cartilage regeneration and other chondrogenesis-related conditions.
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Acan Aggrecan
ChIP Chromatin immunoprecipitation
DAPI 2-(4-amidinophenyl)-1H-indole-6-carboxamidine
DMEM Dulbecco’s modified Eagle’s medium
ENU N-ethyl-N-nitrosourea
FBS Fetal bovine serum
Gapdh Glyceraldehyde 3-phosphate dehydrogenase
IF Immunofluorescent
Ihh Indian hedgehog
Nfat5 Nuclear factor of activated T-cells 5
Nfatc1 Nuclear factor of activated T-cells 1
Patched1 Patched homology 1
qPCR Quantitative real-time PCR
RNAi RNA interference
RT Reverse transcription
Runx1 Runt-related transcription factor 1
Runx2 Runt-related transcription factor 2
Runx3 Runt-related transcription factor 3
Tlx1 T-cell leukemia, homeobox1
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